News Search Results
Jan 11, 2024, 05:30 ET Orthokeratology Lens Global Market Forecast Report to 2028 - Consumers Preferring Non-Surgical Vision Treatment
by an orthokeratology lens. Older adults may lose the ability to see up close and ability to distinguish between colors. The American Academy of Ophthalmology recommends regular eye checkups for people aged 65 or above with an initial checkup at 40 years of age. The ageing population is growing,
More news about: Research and Markets
Jan 09, 2024, 15:23 ET Two PMB Projects Named 2023 HREI Insights™ Award Finalists
health and rehabilitation, perinatal education, OB/GYN clinical offices, comprehensive imaging, conference / education rooms, medical oncology, ophthalmology, orthopedics, surgery center, urology, urgent care, blood draw and a Blue Bowl Superfoods outlet. Visitors and tenants also will have access to
More news about: PMB
Jan 09, 2024, 08:30 ET Creation of the Emmes Group Will Advance Company's 47-year Legacy and Build Clinical Research Infrastructure for the Future
clinical service providers to the U.S. government with industry-leading capabilities in cell and gene therapy, vaccines and infectious diseases, and ophthalmology. "AI is now helping us learn the language of biology to rapidly generate disease insights and advance new treatments," Chilukuri continued.
More news about: EMMES
Jan 09, 2024, 08:00 ET Embold Health Granted Patents on Novel Approach to Measuring Physician Quality, Provider Search Tools for Employers & Employees
when seeking care. In 2024, Embold will continue to expand its platform to include additional clinical specializations, including urology, ophthalmology, general surgery, lung cancer surgery and breast cancer surgery. For current customers, Embold will also be introducing new technology enhancements
More news about: Embold Health
Jan 08, 2024, 19:00 ET Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the first Phase 3 clinical trial of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1
More news about: Innovent Biologics
Jan 08, 2024, 12:00 ET Vision Innovation Partners Announces Acquisition of Bucks-Mont Eye Associates
PA. BMEA marks VIP's 25th add-on acquisition since its founding in 2017 and strengthens its growing network of differentiated ophthalmology practices. BMEA is a premier provider of ophthalmologic, optometric, and retina care in Bucks and
More news about: Gryphon Investors
Jan 08, 2024, 09:00 ET Novaestiq Unveils Platform of Innovations; Poised to Disrupt the US Aesthetic Market
Australia/New Zealand. It also operates as a contract manufacturer in orthopedics and ophthalmology.
More news about: Novaestiq
Jan 08, 2024, 09:00 ET Novaestiq Unveils Platform of Innovations; Poised to Disrupt the US Aesthetic Market
Australia/New Zealand. It also operates as a contract manufacturer in orthopedics and ophthalmology.
More news about: Novaestiq
Jan 07, 2024, 14:00 ET Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA). Additional information:
More news about: Specialised Therapeutics
Jan 05, 2024, 11:26 ET International Eye Associates Joins the Florida Eye Specialists Network
and education centers. The office offers a comprehensive range of eye care services, including cataracts, cornea, dry eye, glaucoma, and general ophthalmology. Dr. Koike, a board-certified, fellowship-trained ophthalmologist, focuses on the cornea, complex cataracts, and glaucoma. He remains at
More news about: Florida Eye Specialists
Jan 05, 2024, 11:24 ET Vitreous Retina Macula Consultants of New York's K. Bailey Freund, MD Serves As Program Director of the Atlantic Coast Retina Club (ACRC) and Macula Conference
diagnosis, treatment, and care of patients with all retinal disorders. In addition to his work with VRMNY, Dr. Freund is a Clinical Professor of Ophthalmology at The NYU Grossman School of Medicine. He is an attending surgeon at Manhattan Eye, Ear and Throat Hospital and New York Presbyterian Hospital.
More news about: Vitreous Retina Macula Consultants of New York
Jan 04, 2024, 09:00 ET Florida Eye Specialists Expands New Cataract Technology Across Northeast Florida
more convenient. "At Florida Eye Specialists, our team is always staying at the forefront of technological advancements in the field of ophthalmology," said CEO and managing partner
More news about: Florida Eye Specialists
Jan 04, 2024, 05:06 ET Eyesafe Wins 2024 CES Innovation Award for Advanced Display Technology Enhancing Power Efficiency and Color
world-class team of eye doctors, engineers, and scientists with decades of experience in electronics, display materials, light management, optometry, and ophthalmology. The Eyesafe brand is trusted by consumers and integrated in millions of digital devices from Dell, HP, Lenovo, LG, ZAGG and more. Eyesafe is recognized
More news about: Eyesafe
Jan 04, 2024, 04:00 ET ZEISS at CES 2024: Multifunctional Smart Glass for a wide range of innovative applications
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: ZEISS Microoptics
Jan 03, 2024, 16:16 ET K2 Medical Research Join Forces with Magruder Eye Institute to Advance Alzheimer's Clinical Trial Accessibility Through RetiSpec's AI-Driven Eye Test
Institute: Magruder Eye Institute is a renowned eye care institution committed to delivering exceptional patient care and advancing the field of ophthalmology through cutting-edge research. With a team of skilled professionals, Magruder Eye Institute has been at the forefront of providing comprehensive
More news about: K2 Medical Research
Jan 03, 2024, 13:17 ET Nearly 100 Physicians from MemorialCare's Long Beach Medical Center, Miller Children's & Women's Hospital Long Beach Recognized by Leading Doctor's Report
otolaryngology, pediatrics, pediatric surgery, endocrinology, rheumatology, maternal/fetal medicine, enterology, gastroenterology, thoracic surgery, ophthalmology, neonatal/perinatal medicine and more. "Our physicians consistently offer exceptional, quality-driven, family-centered care to our patients
More news about: MemorialCare Long Beach Medical Center and MemorialCare Miller Children’s & Women’s Hospital Long Beach
Jan 03, 2024, 09:00 ET Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry
company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see
More news about: Turn Biotechnologies, Inc.
Jan 03, 2024, 08:37 ET Turn Biotechnologies' Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry
company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see
More news about: Turn Biotechnologies
Jan 03, 2024, 03:30 ET SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer
peer-reviewed international ophthalmology journals. He has published four textbooks in ophthalmology and has published over 90 abstracts and manuscripts in peer-reviewed journals in ophthalmology, with numerous invited lectures at national and international ophthalmology meetings. He currently holds
More news about: SpliceBio
Jan 02, 2024, 08:45 ET Hartford HealthCare's Rocky Hill Surgery Center earns The Leapfrog Group's Prestigious "Top Ambulatory Surgery Center" Award for Clinical Quality and Patient Safety
Hartford HealthCare Rocky Hill Surgery Center opened in 2019 in partnership with Hartford HealthCare, CSA and 13 local surgeons who specialize in ophthalmology surgery including cataracts, glaucoma and advanced retinal procedures. Every one of Hartford HealthCare's seven acute care hospitals earned an
More news about: Constitution Surgery Alliance
Jan 01, 2024, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-2) of higher dose
More news about: Innovent Biologics
Dec 29, 2023, 16:56 ET Stuart Therapeutics Announces First Patient, First Visit in its Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease
expanded our portfolio, based on new research results on our mechanism of action, and its applicability to a number of important indications in ophthalmology. In particular, our findings, coupled with the endpoint outcomes in our Phase 2 trial suggest the potential for a fast acting, highly differentiated
More news about: Stuart Therapeutics
Dec 27, 2023, 19:00 ET Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and Xuanzhu Biopharma, today announce that they entered into a clinical trial collaboration and supply agreement for the
More news about: Innovent Biologics
Dec 27, 2023, 06:45 ET Mallinckrodt Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products.
More news about: Mallinckrodt plc
Dec 26, 2023, 19:00 ET Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and Sanegene Bio USA Inc. (SanegeneBio) announce that they have entered into a collaboration
More news about: Innovent Biologics